Cargando…
Serum uric acid, disease severity and outcomes in COVID-19
BACKGROUND: The severity of coronavirus disease 2019 (COVID-19) is highly variable between individuals, ranging from asymptomatic infection to critical disease with acute respiratory distress syndrome requiring mechanical ventilation. Such variability stresses the need for novel biomarkers associate...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201458/ https://www.ncbi.nlm.nih.gov/pubmed/34127048 http://dx.doi.org/10.1186/s13054-021-03616-3 |
_version_ | 1783707820590366720 |
---|---|
author | Dufour, Inès Werion, Alexis Belkhir, Leila Wisniewska, Anastazja Perrot, Marie De Greef, Julien Schmit, Gregory Yombi, Jean Cyr Wittebole, Xavier Laterre, Pierre-François Jadoul, Michel Gérard, Ludovic Morelle, Johann |
author_facet | Dufour, Inès Werion, Alexis Belkhir, Leila Wisniewska, Anastazja Perrot, Marie De Greef, Julien Schmit, Gregory Yombi, Jean Cyr Wittebole, Xavier Laterre, Pierre-François Jadoul, Michel Gérard, Ludovic Morelle, Johann |
author_sort | Dufour, Inès |
collection | PubMed |
description | BACKGROUND: The severity of coronavirus disease 2019 (COVID-19) is highly variable between individuals, ranging from asymptomatic infection to critical disease with acute respiratory distress syndrome requiring mechanical ventilation. Such variability stresses the need for novel biomarkers associated with disease outcome. As SARS-CoV-2 infection causes a kidney proximal tubule dysfunction with urinary loss of uric acid, we hypothesized that low serum levels of uric acid (hypouricemia) may be associated with severity and outcome of COVID-19. METHODS: In a retrospective study using two independent cohorts, we investigated and validated the prevalence, kinetics and clinical correlates of hypouricemia among patients hospitalized with COVID-19 to a large academic hospital in Brussels, Belgium. Survival analyses using Cox regression and a competing risk approach assessed the time to mechanical ventilation and/or death. Confocal microscopy assessed the expression of urate transporter URAT1 in kidney proximal tubule cells from patients who died from COVID-19. RESULTS: The discovery and validation cohorts included 192 and 325 patients hospitalized with COVID-19, respectively. Out of the 517 patients, 274 (53%) had severe and 92 (18%) critical COVID-19. In both cohorts, the prevalence of hypouricemia increased from 6% upon admission to 20% within the first days of hospitalization for COVID-19, contrasting with a very rare occurrence (< 1%) before hospitalization for COVID-19. During a median (interquartile range) follow-up of 148 days (50–168), 61 (12%) patients required mechanical ventilation and 93 (18%) died. In both cohorts considered separately and in pooled analyses, low serum levels of uric acid were strongly associated with disease severity (linear trend, P < 0.001) and with progression to death and respiratory failure requiring mechanical ventilation in Cox (adjusted hazard ratio 5.3, 95% confidence interval 3.6–7.8, P < 0.001) or competing risks (adjusted hazard ratio 20.8, 95% confidence interval 10.4–41.4, P < 0.001) models. At the structural level, kidneys from patients with COVID-19 showed a major reduction in urate transporter URAT1 expression in the brush border of proximal tubules. CONCLUSIONS: Among patients with COVID-19 requiring hospitalization, low serum levels of uric acid are common and associate with disease severity and with progression to respiratory failure requiring invasive mechanical ventilation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03616-3. |
format | Online Article Text |
id | pubmed-8201458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82014582021-06-15 Serum uric acid, disease severity and outcomes in COVID-19 Dufour, Inès Werion, Alexis Belkhir, Leila Wisniewska, Anastazja Perrot, Marie De Greef, Julien Schmit, Gregory Yombi, Jean Cyr Wittebole, Xavier Laterre, Pierre-François Jadoul, Michel Gérard, Ludovic Morelle, Johann Crit Care Research BACKGROUND: The severity of coronavirus disease 2019 (COVID-19) is highly variable between individuals, ranging from asymptomatic infection to critical disease with acute respiratory distress syndrome requiring mechanical ventilation. Such variability stresses the need for novel biomarkers associated with disease outcome. As SARS-CoV-2 infection causes a kidney proximal tubule dysfunction with urinary loss of uric acid, we hypothesized that low serum levels of uric acid (hypouricemia) may be associated with severity and outcome of COVID-19. METHODS: In a retrospective study using two independent cohorts, we investigated and validated the prevalence, kinetics and clinical correlates of hypouricemia among patients hospitalized with COVID-19 to a large academic hospital in Brussels, Belgium. Survival analyses using Cox regression and a competing risk approach assessed the time to mechanical ventilation and/or death. Confocal microscopy assessed the expression of urate transporter URAT1 in kidney proximal tubule cells from patients who died from COVID-19. RESULTS: The discovery and validation cohorts included 192 and 325 patients hospitalized with COVID-19, respectively. Out of the 517 patients, 274 (53%) had severe and 92 (18%) critical COVID-19. In both cohorts, the prevalence of hypouricemia increased from 6% upon admission to 20% within the first days of hospitalization for COVID-19, contrasting with a very rare occurrence (< 1%) before hospitalization for COVID-19. During a median (interquartile range) follow-up of 148 days (50–168), 61 (12%) patients required mechanical ventilation and 93 (18%) died. In both cohorts considered separately and in pooled analyses, low serum levels of uric acid were strongly associated with disease severity (linear trend, P < 0.001) and with progression to death and respiratory failure requiring mechanical ventilation in Cox (adjusted hazard ratio 5.3, 95% confidence interval 3.6–7.8, P < 0.001) or competing risks (adjusted hazard ratio 20.8, 95% confidence interval 10.4–41.4, P < 0.001) models. At the structural level, kidneys from patients with COVID-19 showed a major reduction in urate transporter URAT1 expression in the brush border of proximal tubules. CONCLUSIONS: Among patients with COVID-19 requiring hospitalization, low serum levels of uric acid are common and associate with disease severity and with progression to respiratory failure requiring invasive mechanical ventilation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03616-3. BioMed Central 2021-06-14 /pmc/articles/PMC8201458/ /pubmed/34127048 http://dx.doi.org/10.1186/s13054-021-03616-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Dufour, Inès Werion, Alexis Belkhir, Leila Wisniewska, Anastazja Perrot, Marie De Greef, Julien Schmit, Gregory Yombi, Jean Cyr Wittebole, Xavier Laterre, Pierre-François Jadoul, Michel Gérard, Ludovic Morelle, Johann Serum uric acid, disease severity and outcomes in COVID-19 |
title | Serum uric acid, disease severity and outcomes in COVID-19 |
title_full | Serum uric acid, disease severity and outcomes in COVID-19 |
title_fullStr | Serum uric acid, disease severity and outcomes in COVID-19 |
title_full_unstemmed | Serum uric acid, disease severity and outcomes in COVID-19 |
title_short | Serum uric acid, disease severity and outcomes in COVID-19 |
title_sort | serum uric acid, disease severity and outcomes in covid-19 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201458/ https://www.ncbi.nlm.nih.gov/pubmed/34127048 http://dx.doi.org/10.1186/s13054-021-03616-3 |
work_keys_str_mv | AT dufourines serumuricaciddiseaseseverityandoutcomesincovid19 AT werionalexis serumuricaciddiseaseseverityandoutcomesincovid19 AT belkhirleila serumuricaciddiseaseseverityandoutcomesincovid19 AT wisniewskaanastazja serumuricaciddiseaseseverityandoutcomesincovid19 AT perrotmarie serumuricaciddiseaseseverityandoutcomesincovid19 AT degreefjulien serumuricaciddiseaseseverityandoutcomesincovid19 AT schmitgregory serumuricaciddiseaseseverityandoutcomesincovid19 AT yombijeancyr serumuricaciddiseaseseverityandoutcomesincovid19 AT wittebolexavier serumuricaciddiseaseseverityandoutcomesincovid19 AT laterrepierrefrancois serumuricaciddiseaseseverityandoutcomesincovid19 AT jadoulmichel serumuricaciddiseaseseverityandoutcomesincovid19 AT gerardludovic serumuricaciddiseaseseverityandoutcomesincovid19 AT morellejohann serumuricaciddiseaseseverityandoutcomesincovid19 AT serumuricaciddiseaseseverityandoutcomesincovid19 |